Loading...
XNAS
FOLD
Market cap3.05bUSD
Dec 05, Last price  
9.90USD
1D
-0.50%
1Q
23.90%
Jan 2017
99.20%
IPO
-26.67%
Name

Amicus Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:FOLD chart
P/E
—
P/S
5.78
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.83%
Rev. gr., 5y
23.72%
Revenues
528m
+32.29%
001,784,00014,967,00064,358,000922,00021,434,00018,411,000363,0001,224,00004,958,00036,930,00091,245,000182,237,000260,886,000305,514,000329,233,000399,356,000528,295,000
Net income
-56m
L-62.99%
-19,972,289-46,344,910-41,167,000-39,355,000-6,567,000-54,936,000-44,412,000-48,785,000-59,633,000-68,926,000-132,118,000-200,042,000-284,002,000-348,995,000-356,388,000-276,852,000-250,460,000-236,568,000-151,584,000-56,106,000
CFO
-34m
L-50.95%
-18,124,349-33,888,79015,192,000-36,863,000-43,371,000-13,983,000-49,422,000-33,744,000-45,794,000-51,669,000-100,139,000-150,534,000-215,485,000-299,955,000-250,416,000-233,290,000-202,491,000-166,575,000-69,091,000-33,891,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
URL
https://www.amicusrx.com/
IPO date
May 31, 2007
Employees
484
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT